{"id":960988,"date":"2026-05-11T17:59:43","date_gmt":"2026-05-11T21:59:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-first-quarter-2026-results\/"},"modified":"2026-05-11T17:59:43","modified_gmt":"2026-05-11T21:59:43","slug":"health-catalyst-reports-first-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-first-quarter-2026-results\/","title":{"rendered":"Health Catalyst Reports First Quarter 2026 Results"},"content":{"rendered":"
\n

SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (\u201cHealth Catalyst,\u201d Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026.<\/p>\n

\u201cWe delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,\u201d said Ben Albert, Chief Executive Officer of Health Catalyst. \u201cMore importantly, this quarter we took the first decisive step toward transforming our operating model and aligning the company around its highest-conviction technology opportunities. This is not a short-term cost exercise. It is a strategic reset designed to build a more focused, durable Health Catalyst capable of meeting the opportunity in front of us. I am confident in the leadership team and board we have assembled to build the intelligence-driven technology company healthcare needs.\u201d<\/p>\n

\n Financial Highlights for the <\/strong>
\n Three Months Ended March 31, 2026<\/strong>\n <\/p>\n

\n
\n Key Financial <\/em>
\n <\/strong>
\n
\n Measures<\/em>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n Three Months Ended March 31,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Year over Year Change<\/strong>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\n GAAP Financial Measures:<\/strong>\n <\/td>\n\n (in thousands, except percentages, unaudited)<\/strong>\n <\/td>\n<\/tr>\n
Total revenue<\/td>\n$<\/td>\n70,756<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n79,413<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(11<\/td>\n)%<\/td>\n<\/tr>\n
Gross profit<\/td>\n$<\/td>\n27,726<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n28,659<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(3<\/td>\n)%<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n39<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n36<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss<\/td>\n$<\/td>\n(111,026<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(23,742<\/td>\n)<\/td>\n\u00a0<\/td>\n(368<\/td>\n)%<\/td>\n<\/tr>\n
\n Non-GAAP Financial Measures:<\/strong>
\n
\n (1)<\/strong>
\n <\/sup>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Gross Profit<\/td>\n$<\/td>\n36,439<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n39,048<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(7<\/td>\n)%<\/td>\n<\/tr>\n
Adjusted Gross Margin<\/td>\n\u00a0<\/td>\n51<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n49<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted EBITDA<\/td>\n$<\/td>\n9,137<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n6,279<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n46<\/td>\n%<\/td>\n<\/tr>\n<\/table>\n

________________________
(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying “Non-GAAP Financial Measures” section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.<\/p>\n

\n Financial Outlook<\/strong>\n <\/p>\n

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.<\/p>\n

For the second quarter of 2026, we expect:<\/p>\n